tiprankstipranks
Trending News
More News >
SAB Biotherapeutics (SABS)
NASDAQ:SABS
US Market

SAB Biotherapeutics (SABS) AI Stock Analysis

Compare
139 Followers

Top Page

SA

SAB Biotherapeutics

(NASDAQ:SABS)

Rating:49Neutral
Price Target:
$2.00
▲(16.96%Upside)
SAB Biotherapeutics struggles with significant financial challenges, weak valuation metrics, and ongoing losses, which weigh heavily on its overall score. The technical indicators offer a glimmer of positive momentum, but not enough to offset the substantial risks associated with its financial instability.
Positive Factors
Clinical Trials
SAB-142's encouraging Phase 1 safety and efficacy in healthy volunteers sets the stage for Phase 2b looking to modulate type 1 diabetes progression.
Dosing Regimen
SAB-142 has a potential competitive dosing regimen with 2-3 days dosing versus 12-14 days with teplizumab, which could be advantageous for outpatient settings.
Market Expansion
The company's plans to potentially pursue other indications for SAB-142 in different stages of type 1 diabetes suggest a broader market opportunity.
Mechanism of Action
SAB-142's multi-target mechanism of action has been clinically validated in type 1 diabetes through several successful clinical trials, further reducing development risk.
Safety Profile
Positive topline data readout showcased sustained immunomodulation and a clean safety profile, positioning SAB-142 as a potential new immunotherapy to prevent and control the progression of type 1 diabetes.
Negative Factors

SAB Biotherapeutics (SABS) vs. SPDR S&P 500 ETF (SPY)

SAB Biotherapeutics Business Overview & Revenue Model

Company DescriptionSAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.
How the Company Makes MoneySAB Biotherapeutics makes money primarily through the development and commercialization of its immunotherapy products. The company generates revenue by engaging in strategic partnerships and collaborations with pharmaceutical companies, government agencies, and other organizations to advance its therapeutic candidates. These partnerships often involve milestone payments, licensing fees, and royalties based on product sales. Additionally, SAB Biotherapeutics may receive funding from grants and government contracts to support the research and development of its antibody therapies. The company's revenue streams are significantly influenced by its ability to successfully bring its products to market and establish lucrative partnerships within the biotechnology sector.

SAB Biotherapeutics Financial Statement Overview

Summary
SAB Biotherapeutics faces significant financial challenges, including a dramatic decline in revenue and persistent losses. The cash flow issues and a high debt-to-equity ratio exacerbate concerns, although the balance sheet provides a modicum of stability.
Income Statement
40
Negative
SAB Biotherapeutics has experienced a significant decline in revenue over recent years, with total revenue falling from $60.88 million in 2021 to just $1.32 million in 2024. The company has maintained negative EBIT and net income, indicating ongoing operational challenges. Margins have remained weak, with a negative net profit margin, reflecting persistent losses.
Balance Sheet
55
Neutral
The company's balance sheet shows a relatively high debt-to-equity ratio, indicating a reliance on debt financing. However, the equity ratio remains reasonable, suggesting some level of financial stability. Stockholders' equity has decreased over the years, which could be a concern if this trend continues.
Cash Flow
30
Negative
SAB Biotherapeutics has faced challenges in generating positive operating cash flow, with significant negative free cash flow in recent years. The company has also shown volatility in financing cash flows, suggesting potential difficulties in maintaining liquidity and funding operations.
Breakdown
TTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
377.83K1.32M2.24M23.90M60.88M55.24M
Gross Profit
-1.43M-3.47M-1.51M20.61M59.22M55.24M
EBIT
-42.29M-42.91M-38.08M-28.92M-13.39M20.56M
EBITDA
-30.38M-28.99M-38.13M-15.12M-15.20M21.14M
Net Income Common Stockholders
-34.28M-34.10M-42.19M-18.74M-17.14M20.12M
Balance SheetCash, Cash Equivalents and Short-Term Investments
12.85M20.76M56.57M15.05M33.21M12.61M
Total Assets
38.12M44.20M83.94M50.90M79.37M56.54M
Total Debt
6.78M4.67M5.91M5.93M6.74M8.13M
Net Debt
1.14M-4.23M-50.66M-9.12M-26.46M-4.48M
Total Liabilities
16.71M18.23M26.64M19.85M40.82M17.53M
Stockholders Equity
21.41M25.97M57.30M31.06M38.55M39.01M
Cash FlowFree Cash Flow
-31.62M-34.63M-25.32M-7.19M-7.19M-2.73M
Operating Cash Flow
-31.41M-34.29M-25.12M3.76M3.76M10.00M
Investing Cash Flow
24.07M-11.96M-152.70K-10.94M-10.94M-12.72M
Financing Cash Flow
-952.19K-1.17M66.77M34.12M34.12M8.98M

SAB Biotherapeutics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.71
Price Trends
50DMA
1.65
Positive
100DMA
1.79
Negative
200DMA
2.50
Negative
Market Momentum
MACD
0.03
Positive
RSI
44.37
Neutral
STOCH
42.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SABS, the sentiment is Negative. The current price of 1.71 is below the 20-day moving average (MA) of 1.83, above the 50-day MA of 1.65, and below the 200-day MA of 2.50, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 44.37 is Neutral, neither overbought nor oversold. The STOCH value of 42.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SABS.

SAB Biotherapeutics Risk Analysis

SAB Biotherapeutics disclosed 80 risk factors in its most recent earnings report. SAB Biotherapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

SAB Biotherapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$5.38B3.27-45.10%3.30%16.81%0.02%
49
Neutral
$17.01M-92.35%-85.48%45.13%
46
Neutral
$11.69M-83.92%-67.87%0.40%
44
Neutral
$18.10M-97.30%-3.23%38.05%
41
Neutral
$25.08M-397.54%24.16%
$9.52M-2264.31%
34
Underperform
$8.20M-174.66%38.53%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SABS
SAB Biotherapeutics
1.71
-1.54
-47.38%
IMNN
Imunon
1.43
0.34
31.19%
ERNA
Eterna Therapeutics
2.29
-27.26
-92.25%
MRKR
Marker Therapeutics
1.60
-3.18
-66.53%
INAB
IN8bio
2.26
-27.74
-92.47%
BOLT
Bolt Biotherapeutics
6.10
-8.98
-59.55%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.